<code id='EDCC9E7C60'></code><style id='EDCC9E7C60'></style>
    • <acronym id='EDCC9E7C60'></acronym>
      <center id='EDCC9E7C60'><center id='EDCC9E7C60'><tfoot id='EDCC9E7C60'></tfoot></center><abbr id='EDCC9E7C60'><dir id='EDCC9E7C60'><tfoot id='EDCC9E7C60'></tfoot><noframes id='EDCC9E7C60'>

    • <optgroup id='EDCC9E7C60'><strike id='EDCC9E7C60'><sup id='EDCC9E7C60'></sup></strike><code id='EDCC9E7C60'></code></optgroup>
        1. <b id='EDCC9E7C60'><label id='EDCC9E7C60'><select id='EDCC9E7C60'><dt id='EDCC9E7C60'><span id='EDCC9E7C60'></span></dt></select></label></b><u id='EDCC9E7C60'></u>
          <i id='EDCC9E7C60'><strike id='EDCC9E7C60'><tt id='EDCC9E7C60'><pre id='EDCC9E7C60'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:126
          Photography of the US department of health and human services in Silver Spring MD
          Manuel Balce Ceneta/AP

          An increasing number of medical device companies are submitting fabricated and unreliable data, the Food and Drug Administration noted Tuesday morning. The data comes from third-party labs hired by device firms to test the quality of their products.

          Triple-check your data or we’ll reject your device, the FDA warned.

          advertisement

          The goal of third-party testing is to ensure a device meets the FDA’s standards in a range of areas, including biocompatibility, sterility, and mechanical performance. The agency wrote that it has noticed an uptick in false data submissions in recent years, particularly from facilities based in China and India. In some cases, the facilities will send data copied from previous device submissions.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M
          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Biogen joins immunology wave with $1.15 billion acquisition of HI

          RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi